NCT05602129Not yet recruitingPhase 2
A Multi-center, Randomized, Open, Positive-controlled Two-stage Phase II Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects
Haisco Pharmaceutical Group Co., Ltd.1 site in 1 country156 target enrollmentStarted: November 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 156
- Locations
- 1
- Primary Endpoint
- Coagulation grade of filter and pipeline
Study Overview
Brief Summary
This study is divided into Stage I and Stage II. It is planned to include 156 subjects who need CRRT treatment for more than 48 hours.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female aged ≥18 and ≤80;
- •16 kg/m2 ≤BMI≤35 kg/m2;
- •Those who need CRRT treatment for more than 48 hours and plan to use CVVHDF treatment mode for femoral vein puncture;
- •Subjects or their guardians voluntarily sign the informed consent form in writing before any procedure related to the study starts, fully understand the purpose and significance of this trial, and are willing to comply with the trial protocol.
Exclusion Criteria
- •Those who are known to be allergic to heparin, heparin drugs, investigational drugs or non-active ingredients of study intervention;
- •Subjects with severe coagulation dysfunction or bleeding tendency three months before the screening, such as HIT (heparin-induced thrombocytopenia), ITP (idiopathic thrombocytopenia purpura), TTP (thrombocytopenia purpura), persistent systolic blood pressure>200 mmHg or diastolic blood pressure>120 mmHg, active gastrointestinal bleeding, intracranial hemorrhage, cerebral aneurysm, severe retinopathy bleeding, hemophilia, hemolytic uremic syndrome, stroke, acute coronary syndrome;
- •Those who have undergone major cardiac surgery or craniocerebral surgery within 3 months before screening and who are judged by the study doctor to be at risk of serious bleeding;
- •Those whose platelet ≤ 50*109/L and/or INR>1.8 and/or aPTT>55s at screening;
- •Those who need to combine other blood purification methods such as blood perfusion or ECMO;
- •The time from the point of randomization to the last use of anticoagulants (low-molecular-weight heparin, warfarin, apixaban, bivalirudin, etc.), antiplatelet drugs (clopidogrel, aspirin, etc.), fibrinolytic drugs (urokinase, etc.) is shorter than the 5 half-lives of the drug or the duration of drug efficacy (calculated by the longest time);
- •The time of administration is shorter than 1 half-life of low-molecular-weight heparin from the last preventive dose;
- •Child-Pugh liver function is grade C in screening period;
- •Those with positive hepatitis C antibody or HIV antibody screening;
- •Pregnant and lactating women; women or men with fertility are unwilling to use contraception throughout the study period; subjects with pregnancy plans within 6 months after the study (including male subjects);
- •Those who have participated in clinical trials of other drugs within 3 months before screening (defined as having received investigational drug or placebo);
- •Other conditions that the investigator judges are not suitable for the subject to participate in the clinical trial.
Arms & Interventions
HSK36273 Continuous infusion
Experimental
Drug:HSK36273 Administration mode:Continuous infusion
Intervention: HSK36273 (Drug)
HSK36273 Bolus+Continuous infusion
Experimental
Drug:HSK36273 Administration mode:Bolus+Continuous infusion
Intervention: HSK36273 (Drug)
Heparin sodium
Active Comparator
Drug:Heparin sodium Administration mode:Bolus+Continuous infusion
Intervention: Heparin sodium (Drug)
Outcomes
Primary Outcomes
Coagulation grade of filter and pipeline
Time Frame: Day1 to Day5
Clotting in the dialyser and the air traps as evaluated by a scale from 0 to 3
Times of filter replacement
Time Frame: Day1 to Day5
the times of filter replacement within 120h after starting administration
Filter life
Time Frame: Day1 to Day5
the time from the start of administration to the first filter replacement and the average filter using time during the treatment period
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Evaluate the Effect of ReSpace™ Hydrogel on Reducing Rectal Radiation Dose in Radiotherapy for Cervical CancerUterine Cervical NeoplasmsNCT05690906Peking Union Medical College Hospital100
Terminated
Phase 1
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic CancerPancreatic Cancer, AdultNCT01834235Precision Biologics, Inc81
Recruiting
Phase 1
A Study of HB0045 Injection in Patients With Advanced Solid TumorsSolid Tumor, AdultNCT06056323Shanghai Huaota Biopharmaceutical Co., Ltd.71
Completed
Phase 2
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.Leukemia, Myeloid, AcuteNCT02450877Celgene7
Completed
Phase 1
A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous NephropathyPrimary Membranous NephropathyNCT05398653Beijing Mabworks Biotech Co., Ltd.94